Partial Breast Radiation to the Lumpectomy Cavity With IMRT in Elderly Women
Phase I/II Trial to Evaluate Partial Breast Radiation to the Region of the Lumpectomy Cavity Using Intensity Modulated Radiation in Elderly Women With Breast Cancer
The standard treatment for women with invasive breast cancer is local excision follow by whole breast radiation. The local recurrence rates are low, side effects are low, and the cosmetic outcome is excellent. The treatments, however, need to be given daily for 5 1/2 to 6 1/2 weeks, making the treatment difficult, particularly for the elderly and for women who need to travel long distances for the therapy. The goal of this study is to determine the toxicity and efficacy of giving the radiation in a shorter time, using higher daily doses of radiation.
The risk of recurrence in the elderly population is lower, and since majority of recurrences occur close to the area where the tumor previously was, it is hypothesized that radiation to that area of the breast would be sufficient to obtain low risk of recurrence. When a smaller volume of tissue is treated, more radiation can be given daily, and therefore the treatment can be shortened. The risk of side effects increases as the dose per daily treatment increases. Therefore, the goal is to study the short term side effects, long term side effects, and cosmetic outcome of daily radiation using higher daily doses for shorter period of time. We will also follow the recurrence rate. Because less of the breast tissue will be treated, there may be a small increased risk of recurrence. Because the higher fraction size can result in more side effects we will be using intensity modulated radiation (IMRT). IMRT is the most advanced individually tailored radiation treatment technique that results in the least amount of side effects. It allows tight monitoring of the dose in the untreated breast.
Seventy five women diagnosed with stage I breast cancer will participate. Participants must have a lumpectomy, clear margins and no lymphovascular invasion to be eligible. A treatment planning CT scan will be obtained. If the lumpectomy cavity can be clearly delineated, an IMRT plan will be generated with predefined strict dose requirement criteria. The patients will be treated once daily, 5 days a week, for a total of 10 treatments (instead of standard 28-33). The patients will be evaluated for toxicity weekly during the treatment, and weekly for additional 4 weeks. At each of these evaluations, they will fill out a short 10 minute questionnaire detailing their side effects. Follow-up will continue every 3 months for 3 years, and every 6 months for 2 more years. At each of these follow-ups a short questionnaire will be filled out by the patients detailing any toxicity, as well as their perception of the cosmetic outcome. A cosmesis questionnaire will be also be filled out by the evaluating physician before radiation, at 6, 12, 18, and 24 months, and yearly for 3 more years. A total of 5 years of follow-up is planned. Participants will also have the option of consenting to the photograph portion of the study. Those who do will have photographs taken of their breasts (excluding faces) at the time they complete the cosmetic questionnaire, to evaluate the cosmetic outcome.
調査の概要
研究の種類
入学
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Vermont
-
Burlington、Vermont、アメリカ、05401
- 募集
- Fletcher Allen Health Care, Radiation Oncology
-
コンタクト:
- Ruth Heimann, M.D., Ph.D.
- 電話番号:802-847-3506
- メール:Ruth.Heimann@vtmednet.org
-
主任研究者:
- Ruth Heimann, M.D., Ph.D.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Stage I ductal breast cancer,
- Status post lumpectomy/partial mastectomy and axillary dissection or sentinel lymph node biopsy
- Age over 65
- Pathologically negative margins
- No lymphovascular invasion
- Able to begin radiation treatment 3-8 weeks post surgery, unless receiving chemotherapy first
- Lumpectomy cavity is visible in CT
- Patient is female
Exclusion Criteria:
- Lymphovascular invasion
- Positive nodes or tumor size greater than 2 cm
- Positive margins
- Age less than 65
- Patient is male
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
|---|
|
Acute sdie effects
|
|
Percent of times that the target definition on planning CT is attained
|
|
Percent of times that the treatment is within the prescription goals
|
二次結果の測定
結果測定 |
|---|
|
美容効果
|
|
Set up variations
|
|
Subacute and long-term side effects
|
|
Percent experiencing local failure, time to recurrence and percent who can be retreated with radiation following recurrence
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ruth Heimann, M.D., Ph.D.、University of Vermont
研究記録日
主要日程の研究
研究開始
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。